Debate on the various anti-vascular endothelial growth factor drugs.
Khalili
Mohammad Reza
MR
Hosseini
Hamid
H
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000627:therapeutic use*; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000150:complications; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D000069579:Ranibizumab; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab